Author Archives: Becky Means

Dr. Joel Diamond Featured on Healthcare de Jure Podcast

Posted by Becky Means on July 28, 2026 | Featured

Host Matt Fisher talks to Dr. Joel Diamond, Chief Medical Officer at Aranscia, about defining genetics, genomics, and molecular testing; switching treatment from body area to specific genetic makeup; the connection to precision medicine and recognizing individual variations; defining pharmacogenetic … Read More

Tags: ClinicalWorkflows, DigitalHealth, Genetics, GenomicMedicine, Genomics, HealthcareInnovation, HealthcarePodcast, HealthcareTechnology, MedicalGenetics, MolecularTesting, PersonalizedMedicine, PharmacogeneticTesting, pharmacogenomics, PrecisionHealth, PrecisionMedicine

DPYD Safety Update: Reducing the Risk of Critical or Fatal Chemotherapy Side Effects

Posted by Becky Means on October 16, 2025 | Featured

Aranscia® solutions help oncologists comply with new FDA warning label requiring DPYD genetic testing in patients receiving select chemotherapies HOUSTON, Oct. 16, 2025 /PRNewswire/ — Oncologists and pharmacy experts are reacting to last week’s Food and Drug Administration warning that requires genetic testing … Read More

Tags: chemotherapy, DPYD, FDA, Oncology

PGx Biomarker Testing: Covered Soon for All Californians

Posted by Becky Means on March 7, 2024 | Featured

Good news for CA providers and residents! Starting July 1, 2024, Pharmacogenomic (PGx) biomarker testing will be a covered benefit for all Californians*, regardless of insurance provider. PGx testing is already a covered benefit for Medicare patients. Read the press … Read More

Tags: ACS CAN, American Cancer Society Cancer Action Network, biomarker, California, Medi-Cal, PGx, pharmacogenomics, SB 496, Senate, University of California